BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Narcolepsy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Narcolepsy\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06952699-11361@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360: Phase 2 readout est. (NCT06952699)
DESCRIPTION:TAK-360\, phase 2\, Narcolepsy.\nStudy: A Study of TAK-360 in A
 dults With Narcolepsy Without Cataplexy (NT2)\nEstimated primary completio
 n: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tak-360#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06952699
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363720-11363@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Orzeyful (Oveporexton): Phase 3 readout est. (NCT07363720)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 3\, Narcolepsy.\nStudy: A Trial 
 of TAK-861 for the Treatment of Narcolepsy With Cataplexy\nEstimated prima
 ry completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/oveporexton#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363720
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455383-10854@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07455383)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07455383
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502443-10854@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07502443)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07502443
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809803-9515@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sodium Oxybate: Phase 2 readout est. (NCT06809803)
DESCRIPTION:Sodium Oxybate\, phase 2\, Narcolepsy.\nStudy: Extended-release
  Sodium Oxybate in Children\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sodium-oxybate#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06809803
URL:https://assetmemo.bio/drug/sodium-oxybate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540897-10854@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07540897)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy\, Safety and Tolerability of ALKS 2680 in Adults With Narcol
 epsy Type 1 (Brilliance NT1 - 304)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/alixorexton#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07540897
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598708-11231@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cleminorexton: Phase 2/3 readout est. (NCT07598708)
DESCRIPTION:Cleminorexton\, phase 2/3\, Narcolepsy.\nStudy: A Study to Inve
 stigate the Effects of Cleminorexton Compared With Placebo in the Treatmen
 t of Participants With Central Disorders of Hypersomnolence\nEstimated pri
 mary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cleminorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07598708
URL:https://assetmemo.bio/drug/cleminorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633301-11361@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20271128
DTEND;VALUE=DATE:20271129
SUMMARY:TAK-360: Phase 2 readout est. (NCT07633301)
DESCRIPTION:TAK-360\, phase 2\, Narcolepsy.\nStudy: A Study of TAK-360 in A
 dults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)\nEstimated primar
 y completion: 28 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tak-360#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07633301
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625280-11034@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 3 readout est. (NCT07625280)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 3\, Narcolepsy.\nStudy: A Study Evaluating the Efficacy and Safety of
  Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH\nE
 stimated primary completion: 23 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxybates-
 xywav#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07625280
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816382-11363@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Orzeyful (Oveporexton): Phase 2/3 readout est. (NCT05816382)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 2/3\, Narcolepsy.\nStudy: A Stud
 y of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions\
 nEstimated primary completion: 28 February 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/oveporexton#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05816382
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767683-10854@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alixorexton: Phase 2/3 readout est. (NCT06767683)
DESCRIPTION:Alixorexton\, phase 2/3\, Narcolepsy.\nStudy: A Long-Term Study
  of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia\nEsti
 mated primary completion: June 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06767683
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646678-11361@assetmemo.bio
DTSTAMP:20261121T004453Z
DTSTART;VALUE=DATE:20310615
DTEND;VALUE=DATE:20310616
SUMMARY:TAK-360: Phase 2/3 readout est. (NCT07646678)
DESCRIPTION:TAK-360\, phase 2/3\, Narcolepsy.\nStudy: A Study of TAK-360 in
  People With Narcolepsy or Idiopathic Hypersomnia\nEstimated primary compl
 etion: 15 June 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tak-360#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07646678
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
